ReviewEuropean journal of clinical pharmacology2026
Clinical pharmacology of antidiabetic drugs: an update.
Review in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis review describes the updated pharmacology of antidiabetic drugs and its translation into clinical applications.
methodsEnglish language literature published from January 1, 1998 to July 25, 2026 was collected using PubMed, ScienceDirect, and Ovid. Research articles, reviews, and clinical practice guidelines were included for discussion.
resultsCurrently, ultra-long-acting basal insulins are emerging, allowing less frequent injections. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), tirzepatide, and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have novel pharmacodynamic properties and clinical evidence of cardiorenal and metabolic benefits, supporting their important roles in individuals with type 2 diabetes (T2D) who have high cardiorenal risk. Because of their effects on weight reduction, GLP-1RAs (semaglutide, liraglutide, and orforglipron) and tirzepatide are approved for the treatment of obesity. Furthermore, SGLT2is (empagliflozin, dapagliflozin, and sotagliflozin) provide cardiorenal benefits, with supporting potential mechanisms, in individuals with heart failure and chronic kidney disease. Conventional oral drugs (e.g., metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sulfonylureas, meglitinides, and α-glucosidase inhibitors) lack sufficient pharmacologic and clinical data on cardiorenal benefits, suggesting their roles as adjunctive therapies. Novel candidates, including triple incretin hormone agonists (acting on GLP-1, glucose-dependent insulinotropic polypeptide [GIP], and glucagon receptors), GLP-1RA-GIP antagonism-based therapies, amylin analogues, and new dual SGLT1/2 inhibitors, show promising results for glycemic control and weight loss.
conclusionOverall, a comprehensive understanding of the pharmacologic characteristics of antidiabetic drugs promotes appropriate drug use for the management of T2D and cardiometabolic diseases and helps avoid undesirable events. Ongoing investigations of novel approaches may contribute to improved patient care in the future.
Indexed as
Identifiers
42993255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.